Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have a consensus "Moderate Buy" on Capricor from 10 firms (9 buys, 1 sell) with an average 12‑month price target of $40.82, and several brokers recently raised targets as high as $50–$54.
• Shares opened at $28.31 with a market cap of about $1.29 billion and a 52‑week range of $4.30–$40.37; the company is unprofitable (latest quarter EPS -$0.54; sell‑side expects roughly -$1.21 for the year).
• Capricor is a clinical‑stage biotech focused on cell and exosome therapies, led by its lead candidate CAP‑1002, being evaluated for Duchenne muscular dystrophy and COVID‑19‑related heart injury.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $40.8182.

A number of equities research analysts have recently commented on the stock. B. Riley reaffirmed a "buy" rating and issued a $50.00 target price (up from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Industrial Alliance Securities set a $48.00 price target on Capricor Therapeutics in a research report on Wednesday, December 3rd. Roth Capital upped their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, November 11th. Oppenheimer increased their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an "outperform" rating in a research report on Monday, December 8th. Finally, Maxim Group boosted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, December 4th.

Capricor Therapeutics Stock Down 1.9%

Shares of NASDAQ CAPR opened at $28.31 on Monday. The business has a 50-day moving average price of $16.05 and a 200 day moving average price of $10.51. The stock has a market cap of $1.29 billion, a PE ratio of -15.73 and a beta of 0.22. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). Sell-side analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently bought and sold shares of CAPR. PVG Asset Management Corp purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $91,000. Voleon Capital Management LP purchased a new position in Capricor Therapeutics during the third quarter worth about $311,000. Moneta Group Investment Advisors LLC lifted its position in Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company's stock valued at $248,000 after purchasing an additional 7,000 shares during the period. Brevan Howard Capital Management LP acquired a new stake in Capricor Therapeutics in the third quarter valued at about $123,000. Finally, Raymond James Financial Inc. boosted its holdings in Capricor Therapeutics by 1,629.9% in the 3rd quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company's stock valued at $1,379,000 after purchasing an additional 180,234 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.